Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women

Steven Boonen, Deborah E. Sellmeyer, Kurt Lippuner, Alexander Orlov-Morozov, Ken Abrams, Peter Mesenbrink, Erik F. Eriksen, Paul D. Miller

Research output: Contribution to journalArticle

Abstract

Intravenous bisphosphonates reduce fracture risk but have been associated in rare cases with deteriorating renal-function in cancer patients. The renal effects of zoledronic acid were assessed in osteoporotic postmenopausal women from 27 countries who received three annual infusions of zoledronic acid or a placebo in a randomized, double-blind trial. Serum creatinine, estimated creatinine clearance and urinary protein were measured before and after at least one infusion in a predefined renal safety cohort of 5035 equally divided patients. This group was compared to 7714 patients whose parameters were measured annually. Significantly more transient pre- to post-infusion increases in serum creatinine occurred in zoledronic acid than placebo-treated patients with significant elevations, relative to pre-infusion, only in the second year. All 31 zoledronic acid and 8 of 10 patients on placebo recovered their pre-infusion serum creatinine value within 12 months. No differences in mean changes in serum creatinine, estimated creatinine clearance or adverse renal events were found. We found that transient changes in renal function can occur following an annual zoledronic acid infusion but, in the long term, renal function was not different from control patients.

Original languageEnglish (US)
Pages (from-to)641-648
Number of pages8
JournalKidney International
Volume74
Issue number5
DOIs
StatePublished - Sep 2008
Externally publishedYes

Fingerprint

zoledronic acid
Creatinine
Kidney
Safety
Placebos
Serum
Diphosphonates

Keywords

  • Osteoporosis
  • Postmenopausal
  • Renal
  • Safety
  • Zoledronic acid

ASJC Scopus subject areas

  • Nephrology

Cite this

Boonen, S., Sellmeyer, D. E., Lippuner, K., Orlov-Morozov, A., Abrams, K., Mesenbrink, P., ... Miller, P. D. (2008). Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney International, 74(5), 641-648. https://doi.org/10.1038/ki.2008.193

Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. / Boonen, Steven; Sellmeyer, Deborah E.; Lippuner, Kurt; Orlov-Morozov, Alexander; Abrams, Ken; Mesenbrink, Peter; Eriksen, Erik F.; Miller, Paul D.

In: Kidney International, Vol. 74, No. 5, 09.2008, p. 641-648.

Research output: Contribution to journalArticle

Boonen, S, Sellmeyer, DE, Lippuner, K, Orlov-Morozov, A, Abrams, K, Mesenbrink, P, Eriksen, EF & Miller, PD 2008, 'Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women', Kidney International, vol. 74, no. 5, pp. 641-648. https://doi.org/10.1038/ki.2008.193
Boonen S, Sellmeyer DE, Lippuner K, Orlov-Morozov A, Abrams K, Mesenbrink P et al. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney International. 2008 Sep;74(5):641-648. https://doi.org/10.1038/ki.2008.193
Boonen, Steven ; Sellmeyer, Deborah E. ; Lippuner, Kurt ; Orlov-Morozov, Alexander ; Abrams, Ken ; Mesenbrink, Peter ; Eriksen, Erik F. ; Miller, Paul D. / Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. In: Kidney International. 2008 ; Vol. 74, No. 5. pp. 641-648.
@article{b47d2e9ad9e848c0a091cf8ee75aea9d,
title = "Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women",
abstract = "Intravenous bisphosphonates reduce fracture risk but have been associated in rare cases with deteriorating renal-function in cancer patients. The renal effects of zoledronic acid were assessed in osteoporotic postmenopausal women from 27 countries who received three annual infusions of zoledronic acid or a placebo in a randomized, double-blind trial. Serum creatinine, estimated creatinine clearance and urinary protein were measured before and after at least one infusion in a predefined renal safety cohort of 5035 equally divided patients. This group was compared to 7714 patients whose parameters were measured annually. Significantly more transient pre- to post-infusion increases in serum creatinine occurred in zoledronic acid than placebo-treated patients with significant elevations, relative to pre-infusion, only in the second year. All 31 zoledronic acid and 8 of 10 patients on placebo recovered their pre-infusion serum creatinine value within 12 months. No differences in mean changes in serum creatinine, estimated creatinine clearance or adverse renal events were found. We found that transient changes in renal function can occur following an annual zoledronic acid infusion but, in the long term, renal function was not different from control patients.",
keywords = "Osteoporosis, Postmenopausal, Renal, Safety, Zoledronic acid",
author = "Steven Boonen and Sellmeyer, {Deborah E.} and Kurt Lippuner and Alexander Orlov-Morozov and Ken Abrams and Peter Mesenbrink and Eriksen, {Erik F.} and Miller, {Paul D.}",
year = "2008",
month = "9",
doi = "10.1038/ki.2008.193",
language = "English (US)",
volume = "74",
pages = "641--648",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women

AU - Boonen, Steven

AU - Sellmeyer, Deborah E.

AU - Lippuner, Kurt

AU - Orlov-Morozov, Alexander

AU - Abrams, Ken

AU - Mesenbrink, Peter

AU - Eriksen, Erik F.

AU - Miller, Paul D.

PY - 2008/9

Y1 - 2008/9

N2 - Intravenous bisphosphonates reduce fracture risk but have been associated in rare cases with deteriorating renal-function in cancer patients. The renal effects of zoledronic acid were assessed in osteoporotic postmenopausal women from 27 countries who received three annual infusions of zoledronic acid or a placebo in a randomized, double-blind trial. Serum creatinine, estimated creatinine clearance and urinary protein were measured before and after at least one infusion in a predefined renal safety cohort of 5035 equally divided patients. This group was compared to 7714 patients whose parameters were measured annually. Significantly more transient pre- to post-infusion increases in serum creatinine occurred in zoledronic acid than placebo-treated patients with significant elevations, relative to pre-infusion, only in the second year. All 31 zoledronic acid and 8 of 10 patients on placebo recovered their pre-infusion serum creatinine value within 12 months. No differences in mean changes in serum creatinine, estimated creatinine clearance or adverse renal events were found. We found that transient changes in renal function can occur following an annual zoledronic acid infusion but, in the long term, renal function was not different from control patients.

AB - Intravenous bisphosphonates reduce fracture risk but have been associated in rare cases with deteriorating renal-function in cancer patients. The renal effects of zoledronic acid were assessed in osteoporotic postmenopausal women from 27 countries who received three annual infusions of zoledronic acid or a placebo in a randomized, double-blind trial. Serum creatinine, estimated creatinine clearance and urinary protein were measured before and after at least one infusion in a predefined renal safety cohort of 5035 equally divided patients. This group was compared to 7714 patients whose parameters were measured annually. Significantly more transient pre- to post-infusion increases in serum creatinine occurred in zoledronic acid than placebo-treated patients with significant elevations, relative to pre-infusion, only in the second year. All 31 zoledronic acid and 8 of 10 patients on placebo recovered their pre-infusion serum creatinine value within 12 months. No differences in mean changes in serum creatinine, estimated creatinine clearance or adverse renal events were found. We found that transient changes in renal function can occur following an annual zoledronic acid infusion but, in the long term, renal function was not different from control patients.

KW - Osteoporosis

KW - Postmenopausal

KW - Renal

KW - Safety

KW - Zoledronic acid

UR - http://www.scopus.com/inward/record.url?scp=49749093393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49749093393&partnerID=8YFLogxK

U2 - 10.1038/ki.2008.193

DO - 10.1038/ki.2008.193

M3 - Article

VL - 74

SP - 641

EP - 648

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 5

ER -